The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics

FEBS Letters

article

James Miles¹  Stephen G. Ward⁵  Banafshé Larijani¹ 

[1] Centre for Therapeutic Innovation, Cell Biophysics Laboratory, Department of Life Sciences, & Department of Physics, University of Bath;Cell Biophysics Laboratory, Research Centre for Experimental Marine Biology and Biotechnology ,(PiE) & Instituto Biofisika, ,(UPV/EHU, CSIC), University of the Basque Country;Early Phase Trials and Sarcoma, Institut Bergonié;FASTBASE Solutions S.L. Astondo Bidea;Centre for Therapeutic Innovation, Leukocyte Biology Laboratory, Department of Life Sciences, University of Bath

关键词: adaptive immunity;    CTLA-4/CD80;    FRET/FLIM;    immune checkpoints;    immune surveillance;    innate immunity;    PD-1/PD-L1;   

DOI  :  10.1002/1873-3468.14480

来源: John Wiley & Sons Ltd.

【 摘 要 】

Innate and adaptive immune systems are built-in homeostatic functions of many multicellular organisms and protect the host against foreign pathogens and infections. Dysregulation of the molecular mechanisms of the immune system can result in autoimmune diseases. The immune system can also be harnessed and manipulated to provide targeted cancer therapies, some of them relying on the blockade of immune-checkpoint receptors. Two prominent immune checkpoints, PD-1/PD-L1 and CTLA-4/CD80, comprise receptor–ligand pairs that prevent the host immune cells from attacking host tissues. However, cancer cells upregulate the respective PD-L1 and CD80 ligands for PD-1 and CTLA-4 and thereby evade the host-immune response. Therapeutic drugs that block PD-1/PD-L1 and CTLA-4/CD80 interactions re-enable the immune system to attack cancer cells, but their prognostic biomarker remains challenging. In this review, we discuss how the use of quantitative molecular imaging can be exploited to predict the response to anti-PD-1/PD-L1 therapies and to identify cancer patients who would benefit from them.

【 授权许可】

Unknown